Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]        
Collaboration revenue $ 648 $ 0 $ 2,408 $ 0
Grant revenue 0 0 167 1,526
Total revenue 648 0 2,575 1,526
Operating expenses:        
Research and development 2,522 2,271 4,829 7,178
General and administrative 3,996 810 8,233 2,553
Total operating expenses 6,518 3,081 13,062 9,731
Loss from operations (5,870) (3,081) (10,487) (8,205)
Interest and other income, net 1 6 2 18
Other expense, net (107) (118) (752) (279)
Change in fair value of warrant liabilities (272) 1 (269) 2
Loss on conversion of notes (4,719) 0 (4,719) 0
Net loss (10,967) (3,192) (16,225) (8,464)
Deemed dividends on preferred stock (138) (393) (958) (1,179)
Net loss attributable to common shareholders $ (11,105) $ (3,585) $ (17,183) $ (9,643)
Net loss per share attributable to common shareholders:        
Basic and diluted $ (0.62) $ (11.89) $ (2.75) $ (32.01)
Weighted average number of shares used in net loss per share calculations:        
Basic and diluted 17,925,585 301,494 6,241,947 301,275
Other comprehensive loss:        
Unrealized gain (loss) on available-for-sale securities $ 0 $ 0 $ 0 $ 0
Comprehensive loss $ (11,105) $ (3,585) $ (17,183) $ (9,643)